Celgene Corporation

Henry Chan

Jeonghoon Sun

Kandasamy Hariharan

Mahan Abbasian

Heather K Raymon

David Mikolon

Laure Escoubet

Monica Wai Ling Leung

Konstantinos Mavrommatis

Monica Leung

Carlo Steven Santos

Gustavo Fenalti

Roli Khattri

Christina Valerie Trout

Peter Henry Schafer

Brydon L Bennett

Marilyn Kehry

Philip Chamberlain

Garth E Ringheim

Haralambos Hadjivassiliou

Pilgrim Jackson

Andrew Wurmser

Eun Mi Hur

Sharmistha Acharya

Dan Zhu

Ho Cho

Lisa Morrison

Jeffrey Johnson

Sanaa Torres

Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.

Engineering of an antibody for tumor-selective binding of CD47

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate the activity of SIRPα.

SIRP-α binding proteins and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-&#x3b1; (SIRP&#x3b1;) and modulate the activity of SIRP&#x3b1;.

SIRP-&#x3b1; binding proteins and methods of use thereof

Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.

BCMA-binding antibodies and uses thereof

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

Methods of treating psoriasis using PD-1 binding antibodies

Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

PD-1 binding proteins and methods of use thereof

Growing community of inventors

Poway, CA, United States of America

Henry Chan